High-profile figures in the artificial intelligence industry, including Sam Altman, Dario Amodei, and Elon Musk, have recently called for a slowdown in AI development. The consensus among these leaders suggests a need for more robust safety measures and industry-wide regulations. While Amodei has advocated for independent monitoring, Altman has emphasized the importance of pacing development rather than halting it entirely. The call for caution has been met with varied reactions, including a decline in AI-related stocks and criticism from Chinese state media, which characterized the move as a geopolitical tactic.
Meanwhile, the political landscape regarding AI regulation remains fragmented. In the United States, the Trump administration has prioritized maintaining a competitive edge over China, downplaying potential risks associated with the technology. While some Democratic lawmakers are pushing for legislative action ahead of the midterms, the House Speaker has indicated that Congress is unlikely to lead on new AI mandates. This legislative hesitation contrasts with the growing concerns voiced by some officials, such as Senator Ruben Gallego, who has publicly compared the current state of AI development to an uncontrollable experiment.
Beyond the regulatory debate, researchers are making strides in medical technology. Yuancheng (Ryan) Lu, a geneticist at the Whitehead Institute, has developed a reprogramming technique designed to reverse age-related vision loss. The therapy, which successfully repaired optic nerves in mice, has now progressed to human clinical trials. Lu’s work is currently featured as part of the 2026 Innovators Under 35 list.
Source: MIT Technology Review
暂无评论。快来发表第一条评论吧。